Omalizumab in chronic urticaria: three years, and most stopping is success

Design

Systematic review and meta-analysis of observational studies with reconstructed time-to-event data

Population

4,516 patients with chronic urticaria across eight studies; 3,276 with chronic spontaneous urticaria

Primary outcome

Overall drug survival of omalizumab and reasons for discontinuation

Effect

Median drug survival 3.1 years (95% CI 2.8-3.4); seven-year survival 43-49% in inducible vs 30% in spontaneous urticaria; autoimmune comorbidity HR 2.03 (1.20-3.41) for discontinuation due to lack of efficacy

Eight observational studies covering 4,516 patients with chronic urticaria - 70.1% women, 3,276 with chronic spontaneous urticaria - were pooled by reconstructing individual time-to-event data from published Kaplan-Meier curves and synthesising hazard ratios under a random-effects model.

Median drug survival was 3.1 years (95% CI 2.8-3.4); across seven years of follow-up patients remained on treatment for a mean of 3.75 years (95% CI 3.62-3.87). Seven-year survival was higher in chronic inducible urticaria, with or without concomitant spontaneous disease, at 43-49%, than in chronic spontaneous urticaria alone at 30%. Early discontinuation was mostly because the disease was well controlled. Stopping because of adverse events was uncommon. Two comorbidity signals emerged: autoimmune comorbidity, mainly thyroid, carried a hazard ratio of 2.03 (95% CI 1.20-3.41) for discontinuation due to lack of efficacy, while an atopic background predicted discontinuation because the disease had settled.

This reframes the counselling at the start of treatment. The usual question - how long will I be on this? - now has an answer with a number attached, and the usual anxiety, that the drug will stop working or cause harm, is largely misplaced: people come off omalizumab because they no longer need it. The comorbidity finding is directly actionable. A patient with thyroid autoimmunity should be told at the outset that the chance of an inadequate response is higher, and reviewed on that expectation rather than after a year of assumed failure.

• Check thyroid autoantibody status before starting, and set expectations accordingly
• Tell patients the median time on treatment is about three years, and that most stopping is because the urticaria settles
• Review a patient with autoimmune comorbidity earlier for inadequate response rather than waiting out a full course
• Distinguish inducible from spontaneous urticaria in the record; long-term persistence on treatment differs markedly
• Adverse events were an uncommon reason to stop - do not let that fear drive an early trial of withdrawal

Why it matters

The commonest reason patients stop this drug is that it worked, which is the opposite of what most of them are bracing for.

Don't overread it

Observational drug survival reflects local prescribing and reimbursement practice as well as clinical response.

The statistics, in plain English

These numbers come from reconstructing patient-level data out of published survival curves rather than from the original datasets, which is a validated technique but adds a layer of approximation the confidence intervals do not show. The eight studies are observational, so drug survival reflects prescribing habits, reimbursement rules and local stopping policies as much as biology - a health system that mandates a treatment break will produce shorter drug survival regardless of how well the drug works. The hazard ratio of 2.03 for autoimmune comorbidity has an interval from 1.20 to 3.41, wide enough that the doubling of risk is the direction rather than a precise figure.

Read the rest in the app

You have read your two free briefings this month. The app carries all 27 specialties, every morning, free — and this finding is waiting in it.

Get Daily Doctor — free

Scan to keep reading on your phone. No account needed to start.